Erythropoietin and anemia

Seminars in Nephrology

Volumn 21, Issue 2, 2001, Pages 190-203

  Tong, Eric M ^a   Nissenson, Allen R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 3; INTERLEUKIN 9; IRON; RECOMBINANT ERYTHROPOIETIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COGNITION; DRUG BIOAVAILABILITY; DRUG COST; ERYTHROPOIESIS; HEALTH CARE POLICY; HORMONAL REGULATION; HORMONAL THERAPY; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; MEDICARE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 0035082214     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2001.20939     Document Type: Review

References (202)

1. Cases and observations, illustrative of renal disease accompanied with the secretion of albuminous urine
2. Humoral regulation of red cell production
3. Cloning and expression of the human EPO gene
4. Structural characterization of natural human urinary and recombinant DNA-derived EPO
5. Some chemical properties of human EPO
6. Glycosylation at specific sites of EPO is essential for biosynthesis, secretion and biological function
7. Role of antennary structure of N-linked sugar chains in renal handling of recombinant human EPO
8. Co-localization of EPO mRNA and ecto-5′-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce EPO
9. Identification of the renal EPO-producing cells using transgenic mice
10. Erythropoetin
11. EPO: Structure, control of production, and function
12. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human EPO gene enhancer at a site required for transcriptional activation
13. The liver as a source of extrarenal EPO production
14. Localization of cells producing EPO in murine liver by in situ hybridization
15. Cellular sites of extrarenal and renal EPO production in anaemic rats
16. Expression of a homologously recombined EPO-SV40 T antigen fusion gene in mouse liver: Evidence for EPO production by ITO cells
17. Organ distribution of EPO messenger RNA in normal and uremic rats
18. In vivo and in vitro regulation of the EPO mRNA: Measurement by competitive polymerase chain reaction
19. Identification of the renal-erythropoietin cells using transgenic mice
20. Human, rat and mouse kidney cells express functional EPO receptors
21. Disparate differentiation in mouse hematopoietic colonies derived from paired progenitors
22. The mechanism of action of EPO
23. Erythropoietic precursors in mice under erythropoietic stimulation and suppression
24. Erythopoietin: Physiologic basis for clinical applications
25. Induction of hemoglobin-synthesizing cells by EPO in vitro
26. Human interleukin-9 supports formation of a subpopulation of erythroid bursts that are responsive to interleukin-3
27. Human interleukin-9 specifically stimulates proliferation of CD34++ DR++ CD33 - Erythroid progenitors in normal human bone marrow in the absence of serum
28. Combination of recombinant colony stimulating factors are required for optimal hematopoietic differentiation in serum-derived culture
29. Human colony-forming units-erythroid do not require accessory cells but do require direct interaction with insulin-like growth factors 1 and/or insulin for erythroid development
30. The kit ligand, stem cell factor
31. Diamand-Blackfan anemia: In vitro response of erythroid progenitors to the ligand for c-kit
32. In vitro growth and regulation of bone marrow enriched CD34+ hematopoietic progenitors in Diamond-Blackfan anemia
33. Diamond-Blackfan anemia: Heterogeneous response of hematopoietic progenitors cells in vitro to the protein product of the Steel locus
34. Properties of cells that produce erythrocytic colonies in vitro
35. EPO
36. Effects of antioxidant vitamins on renal and hepatic EPO production
37. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon
38. Effect of inflammatory cytokines on hypoxia-induced EPO production
39. Tumor necrosis factor alpha and hematopoietic progenitors: Effect of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines k62, HL60, and HEL cells
40. Neocytolysis: A physiologic down-regulator of red blood cell mass
41. Control of red blood cell mass in spaceflight
42. Neocytolysis in the adaptation of red cell mass on descent from altitude
43. Neocytolysis on descent from altitude
44. Neocytolysis contributes to the anemia of renal disease
45. Expression cloning of the murine EPO receptor
46. The molecular biology of EPO receptors
47. Specific recruitment of SH-PTP1 to the EPO receptor causes inactivation of JAK2 and termination of proliferative signals
48. EPO retards DNA breakdown and prevents programmed death in erythroid progenitor cells
49. Pharmacokinetics of recombinant human EPO administered in hemodialysis patients
50. In vivo 125I-EPO pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep
51. Physiological and pharmacodynamic considerations for route of EPO administration
52. Reduced production, absorption, and elimination of EPO in uremia compared with healthy volunteers
53. Clinical pharmacology and economics of EPO is essential for biosynthesis, secretion, and biological function
54. Comparative pharmacokinetics of and pharmacodynamics of epoetin alfa and epoetin beta
55. Single dose kinetics or recombinant human EPO after intravenous subcutaneous and intraperitoneal administration
56. Pharmacokinetics of intravenous, intraperitoneal, and subcutaneous recombinant EPO in patients on CAPD
57. The pharmacokinetics of intraperitoneal EPO administered undiluted or diluted in dialysate
58. Pharmacokinetics and erythropoietic response to human recombinant EPO in healthy men
59. Single dose kinetics or recombinant human EPO after intravenous, subcutaneous and intraperitoneal administration
60. Pharmacokinetics of recombinant EPO in chronic haemodialysis patients
61. Comparative pharmacokinetics of recombinant EPO administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients
62. Pharmacokinetics of intravenous, intraperitoneal, and subcutaneous recombinant EPO in patients on CAPD
63. Pharmacokinetics of recombinant human EPO after subcutaneous administration and in long-term IV treatments in patients on maintenance hemodialysis
64. Optimal route of administration of EPO in chronic renal failure patients: Intravenous versus subcutaneous
65. Subcutaneous treatment with recombinant EPO-The influence of injection frequency and skin-fold thickness
66. RHuEPO clinical practice guidelines for the treatment of anemia of chronic renal failure
67. The pharmacokinetics and pharmacodynamics or recombinant human erythropietin in hemodialysis patients
68. Subcutaneous versus intravenous administration of EPO improves its efficacy for the treatment of anaemia in hameodialysis patients
69. Safety and efficacy of low dose subcutaneous EPO in hemodialysis patients
70. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis
71. EPO response and route of administration
72. Experience with daily self-administered subcutaneous EPO
73. Subcutaneous EPO: A comparison of daily and thrice weekly administration
74. Primary results from the US multicenter pediatric recombinant erythropoietin study
75. Effect of recombinant human erythropoietin treatment on renal anemia and body growth of children with end-stage renal disease
76. Recombinant human EPO in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial
77. Treatment of the anemia of progressive renal failure with recombinant human EPO
78. The USRDS dialysis morbidity and mortality study (Wave 1)
79. Poor response to treatment in renal anaemia with EPO corrected by iron given intravenously
80. Current concepts of anemia management in chronic renal failure: Impact of NKF-DOQI
81. How to get the best out of r-HuEPO
82. Efficacy and adverse effects of oral iron supplements
83. EPO fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo
84. Poor response to EPO in inflammatory conditions may be mediated by interleukin-6
85. The anemia of chronic disorders: Studies of marrow regulation and iron metabolism
86. High C-reactive protein is a strong predictor of resistance to EPO in hemodialysis patients
87. Acute-phase response predicts EPO resistance in hemodialysis and peritoneal dialysis patients
88. Effect of enalapril on haemoglobin and serum EPO in patients with chronic nephropathy
89. Posttransplant erythrocytosis: An enigma revisited
90. Renin-angiotensin system stimulates EPO secretion in chronic hemodialysis patients
91. Captopril and lisinopril suppresses production of interleukin-12 by human peripheral blood mononuclear cells
92. Angiotensin II stimulates proliferation of normal early progenitors
93. Angiotensin-converting enzyme inhibitors and higher EPO requirement in chronic haemodialysis patients
94. ACE inhibitors do not induce recombinant human EPO resistance in hemodialysis patients
95. Unresponsiveness to recombinant human EPO in haemodialysis patients: Possible implications of angiotensin convening enzyme inhibitors
96. High dose enalapril impairs the response to EPO treatment in haemodialysis patients
97. Chloramine-induced haemolysis presenting as EPO resistance
98. EPO resistance due to dialysate chloramine: The two-way traffic of solutes in haemodialysis
99. Chloramines in municipal water: Considerations for dialysis facilities
100. Carnitine abnormalities in patients with renal insufficiency: Pathophysiological and therapeutic aspects
101. Carnitine balance in hemodialyzed patients
102. Carnitine levels in human serum in health and disease
103. Long-term L-carnitine treatment of chronic anemia of patients with end-stage renal failure
104. Effect of L-carnitine and acetyl-L-carnitine on the human erythrocyte membrane stability and deformability
105. The response to recombinant human EPO in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels
106. Effects of low doses of L-carnitine on the response to recombinant human EPO in hemodialyzed children: About two cases
107. L-carnitine effects on anemia in hemodialyzed patients treated with EPO
108. Anemia and carnitine supplementation in hemodialyzed patients
109. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to EPO in uremia
110. Serum EPO and erythropoiesis in primary and secondary hyperparathyroidism: Effects of parathyroidectomy
111. Elevation of serum EPO after subtotal parathyroidectomy in chronic hemodialysis patients
112. Effect of parathyroidectomy on anemia in chronic renal failure
113. Anemia and secondary hyperparathyroidism
114. Secondary hyperparathyroidism as cause of resistance to treatment with EPO: Effect of parathyroidectomy
115. Intravenous calcitriol improves anaemia and reduces the need for EPO in haemodialysis patients
116. Control of secondary hyperparathyroidism with 'pulse' oral calcitriol improves anemia in haemodialysis patients under maintenance EPO therapy
117. Association between recombinant human EPO and quality of life and exercise capacity of patients receiving hemodialysis
118. Changes in quality of life at comparative levels of hemoglobin after long-term treatment with EPO
119. The quality of life of hemodialysis patients treated with recombinant human EPO
120. The clinical evaluation of chemotherapeutic agents in cancer
121. The sickness impact profile: Development and final revision of health-status measure
122. Quality of life in dialysis patients. A Spanish multicentre study
123. Recombinant EPO: 10 years of clinical experience
124. Treatment of anaemia in haemodialysis patients with EPO
125. Appropriate hematocrit levels of EPO supplementary therapy in end-stage renal failure complicated by coronary artery disease
126. Sensitization to human leukocyte antigen before and after the introduction of EPO
127. The quality of life in renal transplantation-a prospective study
128. Recombinant human EPO treatment may improve quality of life and cognitive function in chronic hemodialysis patients
129. Recombinant human EPO: Impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life
130. Central nervous system function in dialysis patients: A practical approach
131. Epoetin and cognitive function
132. Red blood cell disorders and stroke
133. Improvement of brain function in hemodialysis patients treated with EPO
134. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients
135. Effects of rHuEPO on Q-EEG and event-related potentials in chronic renal failure
136. Cognitive function, mood and P3 latency: Effects of the amelioration of anemia in dialysis patients
137. Normalizing hematocrit in dialysis patients improves brain function
138. Complications of long-term dialysis: Cardiovascular complications and cardiac risk factor interventions
139. Cardiac disease in chronic uremia: Pathogenesis
140. What are the short and long-term consequences of anemia in CRF patients?
141. Vascular changes in hemodialysis patients in response to recombinant human EPO
142. Long-term evolution of cardiomyopathy in dialysis patients
143. The prognostic importance of left ventricular geometry in uremic cardiomyopathy
144. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease
145. Vascular changes in hemodialysis patients in response to recombinant human EPO
146. Therapy with recombinant human EPO reduces cardiac size and improves cardiac function in chronic hemodialysis patients
147. Long term myocardial effects of correction of anemia with recombinant EPO in aged patients on hemodialysis
148. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant human EPO
149. Renormalization of high cardiac output and left ventricular size following long term recombinant human EPO treatment of anemia dialyzed uremic patients
150. Hemodynamic changes in hemodialyzed patients during treatment with recombinant human EPO
151. Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human EPO
152. Hemodynamic effect of recombinant human EPO on hypotensive hemodialysis patients
153. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human EPO
154. Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human EPO
155. Regression of left ventricular hypertrophy after partial correction of anemia with EPO in patients on hemodialysis: A prospective study
156. A randomized controlled trial of complete vs. partial correction of anemia in hemodialysis patients with asymptomatic LV hypertrophy or LV dilatation
157. The effects of normal as compared with low hematocrit in patients with cardiac disease who are receiving hemodialysis and epoetin
158. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy
159. Anemia in hemodialysis patients: Variable affecting this outcome predictor
160. Hematocrit level and associated mortality in hemodialysis patients
161. Clinical factors associated with changing Hct levels in hemodialysis patients
162. Changes in Hct and risk of mortality
163. Change in Hct and risk of hospitalizations
164. Effect of recombinant human EPO on hospitalization of hemodialysis patients
165. Hematocrit levels and hospitalization risks in hemodialysis patients
166. Blood pressure in hemodialysis patients during amelioration of anemia with EPO
167. Hypertension following EPO therapy in anemic hemodialysis patients
168. Effects of EPO on blood pressure
169. Mechanism of EPO-induced hypertension
170. Effects of normal hematocrit on ambulatory blood pressure in Epoetin-treated hemodialysis patients with cardiac disease
171. Intravenous EPO (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients
172. Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human EPO
173. EPO-induced hypertension in rat is not mediated by alterations of plasma endothelin, vasopressin, or atrial natriuretic peptide levels
174. Lack of a fast-acting effect of EPO on arterial blood pressure and endothelin levels
175. Differential effects of endothelin-1 antagonists on EPO-induced hypertension in renal failure
176. Exposure of endothelial cells to recombinant human EPO induces nitric oxide synthase activity
177. In vivo and in vitro pressor effects of EPO in rats
178. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance EPO therapy
179. EPO increases cytosolic free calcium concentration and thrombin induced changes in cytosolic free calcium in platelets from spontaneously hypertensive rats
180. EPO modulation of intracellular calcium: A role for tyrosine phosphorylation
181. Blood pressure changes during treatment with recombinant human EPO
182. Role of nitric oxide resistance in EPO-induced hypertension in rats with chronic renal failure
183. Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human EPO
184. Morbidity and mortality in hemodialysis patients with and without EPO treatment. A controlled study
185. Correction of the anemia of end-stage renal disease with recombinant human EPO: Results of a combined phase I and II clinical trial
186. Morbidity and mortality in hemodialysis patients with and without EPO treatment. A controlled study
187. Use of recombinant human EPO (rH-EPO) in the treatment of anemia in hemodialysis patients: A multicenter Italian experience
188. Cost benefits of low dose subcutaneous EPO in patients with anaemia of ESRD
189. Adverse events of subcutaneous recombinant human EPO therapy: Results of a controlled multicenter European study
190. EPO stimulates proliferation of human renal carcinoma cells
191. Haemoglobin-is more better?
192. Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients
193. Optimal hematocrit for the maximum oxygen delivery to the brain with recombinant human erythropoietin in hemodialysis patients
194. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients
195. Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients
196. Cardiac function in patients with end-stage renal disease after normalization of hemoglobin with erythropoietin. American Society of Nephrology
197. Physical exercise capacity in patients with end-stage renal disease after normalization of hemoglobin with erythropoietin. American Society of Nephrology
198. A randomized controlled trial of complete vs partial correction of anemia in hemodialysis patients with asymptomatic concentric LV hypertrophy or LV dilatation. M1127, American Society of Nephrology
199. Secular trends in recombinant erythropoietin therapy among the US hemodialysis population: 1990-1996
200. Hematocrit levels and associated Medicare expenditures
201. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients